Thank you, Paul. The continued momentum in both our U.S. and international businesses during Q3 saw over 14 million average ...

Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Secured FDA alignment on key ...